Dendritic cell cross‐dressing and tumor immunity

  • Martinez‐Usatorre A
  • De Palma M
15Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In addition to direct and cross-presentation, dendritic cells (DCs) can present tumor antigens (TAs) to T cells via a hitherto poorly understood mechanism called "cross-dressing." DC cross-dressing involves the acquisition of preformed peptide-major histocompatibility class I/II (p-MHC) complexes from cancer cells. This process has been documented both in cell culture and in tumor models; may occur via the uptake of tumor-derived extracellular vesicles or the horizontal transfer of plasma membrane fragments from cancer cells to DCs; and can be enhanced through DC engineering for therapeutic applications. In some experimental contexts, DC cross-dressing may be essential for productive anti-tumor immunity, possibly owing to the fact that tumor-derived p-MHC complexes encompass the full repertoire of immunologically relevant TAs against which primed cytotoxic T cells can exert their tumoricidal activity.

Cite

CITATION STYLE

APA

Martinez‐Usatorre, A., & De Palma, M. (2022). Dendritic cell cross‐dressing and tumor immunity. EMBO Molecular Medicine, 14(10). https://doi.org/10.15252/emmm.202216523

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free